Class I/II Obesity study: Semaglutide
Official title Translational Health Research Into Vascular and Neurocognitive Effects of Weight Loss
ClinicalTrials.gov ID: NCT07592546
What this study is testing
What is semaglutide?
semaglutide is an investigational medicine, being studied as a potential treatment for class i/ii obesity.
Also referred to as Ozempic, Wegovy.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The goal of this clinical trial is to learn about the nature of brain abnormalities associated with excess body fat in healthy adults aged 35-55. The main questions it aims to answer are: Will excessive fat be associated with brain abnormalities on MRI measures?
- Phase 4: studies an already-approved treatment
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 35 to 55. Healthy volunteers may be eligible.
You may be able to join if
- Individuals of age 35-55 years with BMI 27 - 40 kg/m2
- Able to provide informed consent
- Individuals of age 35-55 years with BMI 20 - 25 kg/m2
- Able to provide informed consent
You likely can't join if
- Current type 2 diabetes mellitus;
- Neurological disorders affecting the CNS;
- History or family history of medullary thyroid carcinoma or MEN2 syndrome
- CNS-active medications (outside of medications used to control psychiatric disorders);
- Poorly controlled psychiatric disorders including major depression or previous suicidality;
- Class III obesity (BMI\>40 or BMI\>35 with complications) as these individuals are eligible for bariatric surgery in Canada and will be referred for...
See the full eligibility criteria
- Individuals of age 35-55 years with BMI 27 - 40 kg/m2
- Able to provide informed consent
- Individuals of age 35-55 years with BMI 20 - 25 kg/m2
- Able to provide informed consent
- Current type 2 diabetes mellitus;
- Neurological disorders affecting the CNS;
- History or family history of medullary thyroid carcinoma or MEN2 syndrome
- CNS-active medications (outside of medications used to control psychiatric disorders);
- Poorly controlled psychiatric disorders including major depression or previous suicidality;
- Class III obesity (BMI\>40 or BMI\>35 with complications) as these individuals are eligible for bariatric surgery in Canada and will be referred for appropriate medical care;
- Clinical safety blood measures indicative of a medical issue.
- History of weight change \> 5 kg in past 90 days;
- History of pancreatitis
- Previous or planned bariatric surgery;
- Use of another weight loss medication during trial participation and within 90 days before enrolment;
- History of serious medical illness, monogenic obesity, uncontrolled hypertension (sBP\>160 mmHg, dBP\>100 mmHg), active malignancy, illicit substance use, cigarette smoking, diagnosed eating disorder, as listed in the...
- Female people of childbearing potential (i.e., a premenopausal female capable of becoming pregnant) are eligible to enroll if they are either sexually inactive/abstinent or using an effective contraceptive from...
The study team makes the final eligibility decision.
Where it is enrolling
- Montreal, Quebec, Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 35 years to 55 years. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Montreal, Quebec, Canada. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.